Andrew Tsai
Stock Analyst at Jefferies
(1.04)
# 3,973
Out of 4,996 analysts
23
Total ratings
40%
Success rate
-18.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Initiates: Buy | $190 | $137.37 | +38.31% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $18.36 | +90.63% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $24.14 | +24.28% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $50.05 | +39.86% | 1 | Jul 14, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $95 → $110 | $106.69 | +3.10% | 1 | Jun 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $3.26 | -23.31% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $116.76 | +71.29% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $19.45 | +38.82% | 2 | Mar 19, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $1.81 | +618.23% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $26.59 | +31.63% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $3.95 | +735.44% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $3.53 | +324.93% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.40 | +114.29% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $320 → $30 | $3.86 | +677.20% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $5.27 | +412.33% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $37.98 | -39.44% | 1 | Jun 1, 2020 |
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $137.37
Upside: +38.31%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $18.36
Upside: +90.63%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $24.14
Upside: +24.28%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $50.05
Upside: +39.86%
Verona Pharma
Jun 11, 2025
Maintains: Buy
Price Target: $95 → $110
Current: $106.69
Upside: +3.10%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.26
Upside: -23.31%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $116.76
Upside: +71.29%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $19.45
Upside: +38.82%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $1.81
Upside: +618.23%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $26.59
Upside: +31.63%
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.95
Upside: +735.44%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $3.53
Upside: +324.93%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.40
Upside: +114.29%
Jun 23, 2022
Downgrades: Hold
Price Target: $320 → $30
Current: $3.86
Upside: +677.20%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $5.27
Upside: +412.33%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $37.98
Upside: -39.44%